Warning! GuruFocus detected
1 Severe warning sign
with CTKB.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cytek Biosciences Inc
NAICS : 423450
SIC : 3845
ISIN : US23285D1090
Description
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.33 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -1.7 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.02 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.7 | |||||
| 3-Year FCF Growth Rate | 281.1 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.77 | |||||
| 9-Day RSI | 30.96 | |||||
| 14-Day RSI | 32.04 | |||||
| 3-1 Month Momentum % | -29.73 | |||||
| 6-1 Month Momentum % | -16.7 | |||||
| 12-1 Month Momentum % | -33.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.86 | |||||
| Quick Ratio | 5.21 | |||||
| Cash Ratio | 4.11 | |||||
| Days Inventory | 209.47 | |||||
| Days Sales Outstanding | 96.18 | |||||
| Days Payable | 17.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.1 | |||||
| Shareholder Yield % | 4.38 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.43 | |||||
| Operating Margin % | -10.24 | |||||
| Net Margin % | -3 | |||||
| FCF Margin % | 10.8 | |||||
| ROE % | -1.54 | |||||
| ROA % | -1.22 | |||||
| ROIC % | -10.5 | |||||
| 3-Year ROIIC % | -21.91 | |||||
| ROC (Joel Greenblatt) % | -22.39 | |||||
| ROCE % | -4.74 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 330 | |||||
| Price-to-Owner-Earnings | 60.61 | |||||
| PS Ratio | 2.61 | |||||
| PB Ratio | 1.31 | |||||
| Price-to-Tangible-Book | 1.44 | |||||
| Price-to-Free-Cash-Flow | 24.54 | |||||
| Price-to-Operating-Cash-Flow | 20.83 | |||||
| EV-to-EBIT | -12.26 | |||||
| EV-to-EBITDA | -25.07 | |||||
| EV-to-Revenue | 1.25 | |||||
| EV-to-FCF | 11.62 | |||||
| Price-to-GF-Value | 0.4 | |||||
| Price-to-Net-Current-Asset-Value | 1.76 | |||||
| Price-to-Net-Cash | 2.96 | |||||
| Earnings Yield (Greenblatt) % | -8.16 | |||||
| FCF Yield % | 4.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTKB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cytek Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 200.453 | ||
| EPS (TTM) ($) | -0.05 | ||
| Beta | 1.52 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 52.64 | ||
| 14-Day RSI | 32.04 | ||
| 14-Day ATR ($) | 0.214397 | ||
| 20-Day SMA ($) | 4.24 | ||
| 12-1 Month Momentum % | -33.08 | ||
| 52-Week Range ($) | 3.97 - 7.63 | ||
| Shares Outstanding (Mil) | 128.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cytek Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cytek Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cytek Biosciences Inc Frequently Asked Questions
What is Cytek Biosciences Inc(CTKB)'s stock price today?
The current price of CTKB is $4.00. The 52 week high of CTKB is $7.63 and 52 week low is $3.97.
When is next earnings date of Cytek Biosciences Inc(CTKB)?
The next earnings date of Cytek Biosciences Inc(CTKB) is 2025-05-08 Est..
Does Cytek Biosciences Inc(CTKB) pay dividends? If so, how much?
Cytek Biosciences Inc(CTKB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers